

# Description of clinical and epidemiological features of hospitalized pediatric patients diagnosed with COVID-19

Descrição das características clínicas e epidemiológicas de pacientes pediátricos internados e diagnosticados com COVID-19

Dayra Aparecida de Almeida Pinheiro<sup>10</sup>, Eliza Lavall Bamberg<sup>10</sup>, Ana Clara Ribeiro de Barros Pereira<sup>10</sup>, Fábio Videira Chagas<sup>10</sup>, Sílvia Paschoalini Azalim de Castro<sup>1,2</sup>

#### **ABSTRACT**

Introduction: Despite the worldwide dissemination of COVID-19, the epidemiological and clinical patterns of the disease remain uncertain in the pediatric age group. Objective: To describe the epidemiological, clinical, laboratory and radiological characteristics of pediatric patients diagnosed with disease caused by SARS-CoV-2, hospitalized in the ward of Hospital Regional João Penido, located in Juiz de Fora, MG. Methods: A cohort study was carried out, with data collection from the period of hospitalization regarding epidemiological, clinical, laboratory and radiological criteria through a specific form developed for the research of pediatric patients, hospitalized from March 11, 2020 to March 11, 2021, who received a diagnosis of COVID-19, confirmed by RT-PCR or by IgM/IgG serology. Results: Of the patients with COVID-19, 49.2% were aged up to 3 years, 66.2% were male and, among the comorbidities, chronic respiratory disease was the most prevalent (26.9%). Most patients had a clinical respiratory condition (72.7%). Regarding disease severity, 38.5% had mild disease, 23.1% moderate, 23.1% severe and 12.3% critical. In the outcome, 98.5% were discharged from the hospital and only 1 patient, who had several comorbidities, died. Conclusion: COVID-19 has varied clinical, radiological and laboratory presentations and, since there is no single or specific treatment, cases must be analyzed and managed individually.

Keywords: Coronavirus; COVID-19; Pediatrics.

- <sup>1</sup> Hospital Regional João Penido/FHEMIG. Juiz de Fora, Minas Gerais, Brazil.
- <sup>2</sup> Universidade Federal de Minas Gerais. Belo Horizonte, Minas Gerais, Brazil.

## Associate Editor Responsible:

Dr. Alexandre Moura

Santa Casa de Misericórdia de Belo Horizonte.

Belo Horizonte/MG, Brazil

#### **Corresponding Author:**

Dayra Aparecida de Almeida Pinheiro E-mail: daayra\_@hotmail.com

#### Supporting sources:

There were no supporting sources.

#### Conflict of Interest:

None.

# **Ethics Committee**

This study was approved by the Research Ethics Committee (CEP) of the Hospital Foundation of the State of Minas Gerais - FHEMIG, under protocol number CAAE 41205020.1.0000.5119.

# Clinical Trial Registration

Not applicable.

## Preprint URL

Not applicable.

Received on: 17 January 2022 Approved on: 18 November 2022 Publication Date: 08 March 2023.

DOI: 10.5935/2238-3182.2022e33102

#### **RESUMO**

Introdução: Apesar da disseminação mundial da COVID-19, os padrões epidemiológicos e clínicos da doença ainda permanecem incertos na faixa etária pediátrica. Objetivo: Descrever as características epidemiológicas, clínicas, laboratoriais e radiológicas dos pacientes pediátricos diagnosticados com doença causada pelo SARS-CoV-2, hospitalizados na enfermaria do Hospital Regional João Penido, situado em Juiz de Fora/MG. Métodos: Foi realizado um estudo do tipo coorte, com coleta de dados do período da internação referente a critérios epidemiológicos, clínicos, laboratoriais e radiológicos através de formulário próprio desenvolvido para a pesquisa de pacientes pediátricos hospitalizados no período de 11 de março de 2020 até 11 de março de 2021, que receberam diagnóstico de COVID-19, confirmado por RT-PCR ou por sorologia IgM/IgG. Resultados: Dos pacientes com COVID-19, 49,2% tinham idade até 3 anos, 66,2% eram do sexo masculino e, dentre as comorbidades, doença respiratória crônica foi a de maior prevalência (26,9%). A maioria dos pacientes apresentou quadro clínico respiratório (72,7%). Com relação à gravidade da doença, 38,5% apresentaram doença leve, 23,1% moderada, 23,1% grave e 12,3% crítica. No desfecho, 98,5% tiveram alta hospitalar e apenas 1 paciente, que possuía diversas comorbidades, evoluiu a óbito. Conclusão: A COVID-19 possui apresentações clínicas, radiológicas e laboratoriais variadas e, não existindo tratamento único ou específico, os casos devem ser analisados e conduzidos de forma individual.

Palavras-chave: Coronavírus; COVID-19; Pediatria.

# **INTRODUCTION**

Coronaviruses belong to the *Coronaviridae* family, order Nidovirales, and are divided into four genera:  $\alpha$ -,  $\beta$ -,  $\gamma$ - and  $\delta$ -coronaviruses.  $\alpha$ - and  $\beta$ -coronaviruses infect only mammals<sup>1</sup>. Among the coronaviruses pathogenic to humans, most are associated with mild clinical symptoms, with two exceptions: the coronaviruses causing severe acute respiratory syndrome (SARS-CoV), a beta-coronavirus that emerged in 2002 and resulted in more than 8,000 human infections and 774 deaths in 37 countries between 2002 and 2003, and the Middle East respiratory syndrome coronavirus (MERS-CoV), first detected in 2012 and responsible for 2,494 laboratory-confirmed cases of infection and 858 fatalities since September 2012<sup>1-3</sup>.

In December 2019, a series of pneumonia cases of unknown cause emerged in Wuhan, Hubei, China, with clinical presentations very similar to viral pneumonia. Sequencing analysis of lower respiratory tract samples indicated a new coronavirus, belonging to the  $\beta$ -coronavirus genus, which was named SARS-CoV-2<sup>1,3-6</sup>.

Epidemiological studies show that patients with comorbidities or older than 60 years have a greater chance of complications, and that SARS-CoV-2 has great infectious Rev Med Minas Gerais 2023; 33: e-33102

potential, with infected patients being the main source of transmission, even when asymptomatic<sup>1,5,7</sup>. However, the pediatric age group did not behave as a risk group, except for the evidence of children under 1 (one) year of age with greater chances of complications<sup>1,3,8</sup>.

Compared to the clinical characteristics of cases in adults, most children diagnosed with the disease have milder symptoms, recover more quickly, transmission time is shorter and the prognosis is good<sup>7,8</sup>. When symptomatic, fever and cough are the most common, but the spectrum of symptoms may also include fatigue, myalgia, nasal congestion, runny nose, sneezing, odynophagia, headache, dizziness, nausea, vomiting, abdominal pain and diarrhea<sup>3,7</sup>. Most children will be treated in outpatient clinics, as asymptomatic, mild or moderate cases represent about 97% of cases<sup>9</sup>. But if there are clinical signs and symptoms suggestive of seriousness, there will be an indication for hospitalization<sup>10</sup>, with about 3% being the number of severe and critical cases with a higher risk of complications<sup>9</sup>.

Despite worldwide dissemination, the epidemiological and clinical patterns of COVID-19 remain uncertain in the pediatric age group, and epidemiological studies are needed to understand and describe the clinical, laboratory and radiological characteristics of hospitalized pediatric patients.

# **METHODS**

A prospective cohort study was carried out, after approval by the Ethics and Research Committee (CEP) of the *Fundação Hospitalar do Estado de Minas Gerais (FHEMIG)* under the embodied opinion nº 41205020.1.0000.5119.

The sample consisted of 65 pediatric patients hospitalized in the ward of the Hospital Regional João Penido (HRJP), in Juiz de Fora - MG, the reference unit for hospitalization of pediatric patients in Zona da Mata Mineira, consisting of 23 beds; with a diagnosis of SARS-CoV-2 confirmed by RT-PCR (reverse transcriptase reaction followed by polymerase chain reaction) or by quantitative IgM/IgG serology, in the period from March 11, 2020, to March 11, 2021, contemplating the first year of the COVID-19 pandemic.

The information was collected in a form developed for the research by searching an electronic medical record in the *Sistema Integrado de Gestão Hospitalar* - Unified System for Hospital Management (SIGH/Intranet). The data underwent a univariate analysis based on epidemiological criteria (age, gender, ethnicity and place of residence - neighborhood/city), clinical (presence of comorbidities, main clinical presentation and other signs and symptoms), laboratory and radiological criteria, treatment and length of stay.

From the data collection, the disease was classified according to severity. Mild cases were those without tachypnea, respiratory effort, drop in oxygen saturation (SatO<sub>2</sub>) or need for oxygen therapy.

Moderate cases were those with tachypnea, wheezing, mild respiratory effort, but without a drop in SatO<sub>2</sub> below 92%. Severe cases were those with moderate to severe respiratory effort and SatO<sub>2</sub> below 92%. Critical cases were those that showed rapid evolution to severe acute respiratory syndrome or respiratory failure and were referred to the intensive care unit (ICU)<sup>1</sup>.

## RESULTS

Of the 65 hospitalized patients confirmed for COVID-19, 63 (97%) were by RT-PCR and 2 (3%) by IgM/IgG serology. There were 43 male patients (66.2%), while 22 (33.8%) were female; aged between 1 day and 13 years and 1 month old.


The epidemiological profile was observed as shown in Table 1 and the municipality of residence of these, with 9 (13.9%) living in other cities and the other 56 (86.1%) were residents of Juiz de Fora, MG, with its distribution by neighborhoods shown on the map represented in Figure 1.

The patients in the sample were referred from different health services, with 52 (80%) transferred from emergency care units, 6 (9.2%) from ICU, 5 (7.8%) from another unit hospital, 1 (1.5%) from rooming-in at the maternity ward and 1 (1.5%) was already admitted to the ward of the HRJP for treatment of another illness. 46 (70.8%) patients had less than 5 days of symptoms at admission, 15 (23%) had between 5 and 10 days of symptoms, and 4 (6.2%) had more than 10 days of symptoms. The comorbidities reported can be analyzed in Table 2.

Table 1. General characteristics of the studied pediatric patients.

	37 • 11	Frequency	
Variable		N	%
	0 - 6 months	14	21.5%
	6m 1d - 11m 29d	4	6.2%
	1y - 2y 11m 29d	14	21.5%
Age	3y - 4y 11m 29d	11	16.9%
	5y - 11y 11m 29d	19	29.3%
	12y - 14y 11m 29d	3	4.6%
	TOTAL	65	100%
	Masculine	43	66.2%
Sex	Feminine	22	33.8%
	TOTAL	65	100%
	White	13	34.2%
Skin Color/Ethnicity	Mixed Race	15	39.5%
	Black	10	26.3%
	Asian	0	0%
	TOTAL	38	100%

The difference between the total of 65 cases studied and the total number of cases in the column of each variable refers to the number of cases without information.



**Figure 1.** Distribution map of neighborhoods in Juiz de Fora, MG, that had patients with COVID-19. **Source:** Image taken from *Google Maps* from data collected for research by the authors.

Of the hospitalized patients, 20 (30.8%) reported contact with an individual with positive COVID-19 at home, 42 (64.6%) reported that other family members were asymptomatic and did not know how to specify the place of infection; 3 (4.6%) had a positive test (nasal secretion *swab* with RT-PCR research for SARS-CoV-2) with less than 24 hours of life and were children of mothers with a history of COVID-19 at some point in their pregnancy, suggesting vertical transmission.

Ten main clinical conditions were identified during hospitalization: 47 (72.7%) had a respiratory condition, 8 (12.3%) had a gastrointestinal condition, 3 (4.5%) had a neurological condition, 2 (3%) were asymptomatic, and of the following situations - condition similar to Kawasaki's disease (KD), acute cardiac dysfunction, dermatological condition, urinary condition and pain crisis - only 1 (1.5%) patient of each was observed. Patients were divided according to their signs and symptoms, as shown in Tables 3 and 4.

Several complementary exams were performed during hospitalization, however, during data collection, only the exams at hospital admission were considered. The medians of the results of these exams were described in Table 5.

Regarding imaging exams, 34 (52.3%) patients had no changes in the chest X-ray, 9 (13.8%) did not undergo the exam, and 22 (33.9%) had changes, of which: 9 (40.9%) with consolidation, 6 (27.3%) with localized interstitial infiltrates, 5 (22.7%) with bilateral diffuse interstitial infiltrates, 3 (13.6%) with atelectasis, 3 (13.6%) with pleural effusion and 3 (13.6%) with hyperinflation.

Chest computed tomography (CT) was performed in 17 (26.2%) patients, of whom 11 (64.7%) had a ground-glass opacity pattern.

Supplementary oxygen was required in 28 (43.1%) patients through various devices, such as nasal catheter in 15 (53.6%) individuals, mask with reservoir in 6 (21.5%), invasive mechanical ventilation in 3 (10.7%) - 2 patients with orotracheal intubation and 1 previously tracheostomized, simple mask in 2 (7.1%) and non-invasive ventilation with positive pressure application in 2 (7.1%). Regarding the duration of oxygen therapy, 8 (28.6%) patients used it for less than 48 hours, 13 (46.4%) used it between 2 and 5 days and 7 (25%) used it for more than 5 days.

In the present sample, 2 (3%) patients were asymptomatic, and among the symptomatic ones, the disease was classified according to severity: 25 (38.5%) had mild, 15 (23.1%) had moderate, 15 (23.1%) had a serious condition and 8 (12.3%) had a critical condition.

Regarding pharmacological treatment, antibiotic therapy was used, with azithromycin being used in 69.2% of patients, ceftriaxone in 37.9% and amoxicillin + clavulanate in 27.6%, other antibiotics were needed according to gravity and crop results. The drug oseltamivir was used in 34 (52.3%) patients. In another 4 (6.2%), it was necessary to associate an antifungal: 2 (50%) used nystatin solution and 2 (50%) used amphotericin B. Corticotherapy was also performed in 41 (63.1%) patients. Hydroxychloroquine was not used in the sample. Salbutamol spray was used in 37 (56.9%) patients.

Table 2. Comorbidities of the studied pediatric patients.

le ·		Frequency	
	N	%	
YES	3	4.6%	
NOT	62	95.4%	
TOTAL	65	100%	
YES	17	27.4%	
		72.6%	
TOTAL	62	100%	
		15.4%	
		84.6%	
TOTAL	65	100%	
		1.5%	
		98.5%	
TOTAL	65	100%	
		7.9%	
	-	92.1%	
TOTAL	63	100%	
<b>T</b> TO 0	_	<b></b>	
		1.5%	
		98.5%	
TOTAL	65	100%	
MEC	0	20.60/	
		29.6%	
		70.4%	
TOTAL	2/	100%	
VEC	0	0	
		0	
		100%	
IOIAL	63	100%	
VEC	1	1 50/	
		1.5%	
		98.5%	
TOTAL	0)	100%	
VEC	1	1 50/-	
		1.5% 98.5%	
		98.5% 100%	
TOTAL	U)	100%0	
YES	1	1.5%	
LLO	1	1.770	
NOT	64	98.5%	
	YES NOT TOTAL  YES NOT TOTAL	YES 3 NOT 62 TOTAL 65  YES 17 NOT 45 TOTAL 62  YES 10 NOT 55 TOTAL 65  YES 1 NOT 64 TOTAL 63  YES 1 NOT 64 TOTAL 65  YES 3 NOT 58 TOTAL 65  YES 1 NOT 64 TOTAL 65  YES 1 NOT 64 TOTAL 65  YES 3 YES 1 NOT 64 TOTAL 65  YES 8 NOT 19 TOTAL 27  YES 0 NOT 63 TOTAL 63  YES 1 NOT 64 TOTAL 65  YES 63  YES 1 NOT 64 TOTAL 65	

The difference between the total of 65 cases studied and the total number of cases in the column of each variable refers to the number of cases without information. \*Associated with congenital laryngomalacia with severe respiratory discomfort, hypoaldosteronism/pseudohypoaldosteronism and neuropsychomotor development delay.

**Table 3.** Signs presented by the studied pediatric patients.

37 11		Frequency	
Variable	-	N	<u> </u>
Fever			
	YES	34	52.3%
	NOT TOTAL	31 65	47.7%
Cough	TOTAL	0)	100%
Cougn	YES	33	50.8%
	NOT	32	49.2%
TT771 .	TOTAL	65	100%
Wheezing	VEC	22	22 00/-
	YES NOT	22 43	33.8% 66.2%
	TOTAL	65	100%
Tachypnoea			
	YES	21	32.3%
	NOT	44	67.7%
Low SpO <sub>2</sub> (<92%)	TOTAL	65	100%
Low 5pO2 (<)270)	YES	19	29.2%
	NOT	46	70.8%
	TOTAL	65	100%
Prostration	VEC	22	25 /0/
	YES NOT	23 42	35.4% 64.6%
	TOTAL	42 65	100%
Thoracic retraction	TOTAL	0)	10070
	YES	22	33.8%
	NOT	43	66.2%
Commo	TOTAL	65	100%
Coryza	YES	30	46.2%
	NOT	35	53.8%
	TOTAL	65	100%
Refusal to feed	MEC	1.5	22.10/
	YES NOT	15 50	23.1% 76.9%
	TOTAL	65	100%
Vomiting	101112	- 0 /	
-	YES	15	23.1%
	NOT	50	76.9%
Diarrhea	TOTAL	65	100%
Diamica	YES	12	18.5%
	NOT	53	81.5%
	TOTAL	65	100%
Dehydration	VEC	7	10.00/
	YES NOT	7 58	10.8% 89.2%
	TOTAL	65	100%
Nasal flaring			
<u> </u>	YES	4	6.2%
	NOT	61	93.8%
Moaning	TOTAL	65	100%
Tytoanning	YES	two	3%
	NOT	63	97%
0 .	TOTAL	65	100%
Cyanosis	YES	1	1.5%
	NOT	64	98.5%
	TOTAL	65	100%
Sore throat			
	YES	3	4.5%
	NOT TOTAL	62 65	95.5%
Crackling	TOTAL	رں	100%
	YES	8	12.3%
	NOT	57	87.7%
	TOTAL	65	100%

Rev Med Minas Gerais 2023; 33: e-33102

RMMG

Variable		Fre	quency
variable		N	%
Snores	MEC	2	20/
	YES	2	3%
	NOT Total	63 65	97% 100%
Rash	TOTAL	0)	10070
Tabii	YES	5	7.7%
	NOT	60	92.3%
	TOTAL	65	100%
Irritability	<b>1</b> /IDO		1.50/
	YES	1	1.5%
	NOT Total	64 65	98.5% 100%
Convulsive Crisis	TOTAL	0)	10070
Son valor ve Sholo	YES	3	4.5%
	NOT	62	95.5%
	TOTAL	65	100%
Eyelid Edema	<b>T</b> TO 0		/ <b>=</b> 0/
	YES	3	4.5%
	NOT Total	62 65	95.5%
Gingivostomatitis	TOTAL	0)	100%
Singivosionianus	YES	1	1.5%
	NOT	64	98.5%
	TOTAL	65	100%
Cervical adenomegaly			
	YES	1	1.5%
	NOT	64	98.5%
Conjunctival and eyelid hype	TOTAL	65	100%
Conjunctival and cyclid hype	YES	1	1.5%
	NOT	64	98.5%
	TOTAL	65	100%
Gear change	<b>T T D</b> O	_	o
	YES	1	1.5%
	NOT Total	64 65	98.5% 100%
Decreased breath sounds	TOTAL	0)	100%
Decreased breath sounds	YES	2	3%
	NOT	63	97%
	TOTAL	65	100%
Petechiae + ecchymosis	<b>1</b> /100		1.50/
	YES	1 64	1.5%
	NOT Total	65	98.5% 100%
Hematuria	TOTAL	0)	10070
1101111111111	YES	1	1.5%
	NOT	64	98.5%
	TOTAL	65	100%
Acute flaccid paralysis	<b>1</b> /100		1.50/
	YES	1 64	1.5%
	NOT Total	65	98.5%
Tachycardia	TOTAL	U)	100%
	YES	1	1.5%
	NOT	64	98.5%
		/-	1000/
	TOTAL	65	100%
Bradycardia			
Bradycardia	YES	1	1.5%
Bradycardia	YES NOT	1 64	1.5% 98.5%
,	YES	1	1.5%
Bradycardia  Jaundice	YES NOT	1 64	1.5% 98.5%
,	YES Not Total	1 64 65	1.5% 98.5% 100%

**Table 4.** Symptoms presented by the pediatric patients studied.

No	able 4. Symptoms presented by th		Frequency	
Headache	Variab	ole		· · · · · · · · · · · · · · · · · · ·
YES         4         6.2%           NOT         61         93.8%           TOTAL         65         100%           Myalgia         YES         two         3%           NOT         63         97%           TOTAL         65         100%           Itching         YES         two         3%           NOT         63         97%           TOTAL         65         100%           Dysuria         YES         1         1.5%           NOT         64         98.5%         100%           Epigastric pain         YES         1         1.5%           NOT         64         98.5%         100%           Chest wall pain         YES         1         1.5%           NOT         64         98.5%         100%           Chest pain         YES         1         1.5%           NOT         64         98.5%         100%           Chest pain         YES         1         1.5%           NOT         64         98.5%         100%           Abdominal pain         YES         1         1.5%           NOT         64         98	Headache			
NOT   61   93.8%     TOTAL   65   100%     Myalgia   YES   two   3%     NOT   63   97%     TOTAL   65   100%     Itching   YES   two   3%     NOT   63   97%     TOTAL   65   100%     TOTAL   65   100%     TOTAL   65   100%     TOTAL   65   100%     Dysuria   YES   1   1.5%     NOT   64   98.5%     TOTAL   65   100%     Epigastric pain   YES   1   1.5%     NOT   64   98.5%     TOTAL   65   100%     TOTAL   65   100%     Chest wall pain   YES   1   1.5%     NOT   64   98.5%     TOTAL   65   100%     Chest pain   YES   1   1.5%     NOT   64   98.5%     TOTAL   65   100%     Chest pain   YES   1   1.5%     NOT   64   98.5%     TOTAL   65   100%     Abdominal pain   YES   1   1.5%     NOT   64   98.5%     TOTAL   65   100%     Pain crisis   YES   1   1.5%     NOT   64   98.5%     TOTAL   65   100%     Pain crisis   YES   1   1.5%     NOT   64   98.5%     TOTAL   65   100%     Dyspnea   YES   1   1.5%     NOT   64   98.5%     TOTAL   65   100%     Dyspnea   YES   1   1.5%     NOT   64   98.5%     TOTAL   65   100%     Dyspnea   YES   1   1.5%     NOT   64   98.5%     TOTAL   65   100%     Dyspnea   YES   1   1.5%     NOT   64   98.5%     TOTAL   65   100%     Dyspnea   YES   1   1.5%     NOT   64   98.5%     TOTAL   65   100%		YES	4	6.2%
Myalgia         YES       two       3%         NOT       63       97%         TOTAL       65       100%         Itching         YES       two       3%         NOT       63       97%         TOTAL       65       100%         Dysuria         YES       1       1.5%         NOT       64       98.5%         TOTAL       65       100%         Epigastric pain         YES       1       1.5%         NOT       64       98.5%         TOTAL       65       100%         Chest wall pain         YES       1       1.5%         NOT       64       98.5%         TOTAL       65       100%         Chest pain         YES       1       1.5%         NOT       64       98.5%         TOTAL       65       100%         Chest wall pain         YES       1       1.5%         NOT       64       98.5%         TOTAL       65       100%         Abdo			61	
YES         two         3%           NOT         63         97%           TOTAL         65         100%           Itching         YES         two         3%           NOT         63         97%           TOTAL         65         100%           Dysuria         YES         1         1.5%           NOT         64         98.5%         100%           Epigastric pain         YES         1         1.5%           NOT         64         98.5%         100%           Chest wall pain         YES         1         1.5%           NOT         64         98.5%         100%           Chest pain         YES         1         1.5%           NOT         64         98.5%         100%           Chest pain         YES         1         1.5%           NOT         64         98.5%         100%           Chest pain         YES         1         1.5%           NOT         64         98.5%         100%           Abdominal pain         YES         1         1.5%           NOT         64         98.5%         100%           <			65	
YES         two         3%           NOT         63         97%           TOTAL         65         100%           Itching         YES         two         3%           NOT         63         97%           TOTAL         65         100%           Dysuria         YES         1         1.5%           NOT         64         98.5%         100%           Epigastric pain         YES         1         1.5%           NOT         64         98.5%         100%           Chest wall pain         YES         1         1.5%           NOT         64         98.5%         100%           Chest pain         YES         1         1.5%           NOT         64         98.5%         100%           Chest pain         YES         1         1.5%           NOT         64         98.5%         100%           Chest pain         YES         1         1.5%           NOT         64         98.5%         100%           Abdominal pain         YES         1         1.5%           NOT         64         98.5%         100%           <	Myalgia			
TOTAL       65       100%         Itching       YES       two       3%         NOT       63       97%         TOTAL       65       100%         Dysuria       YES       1       1.5%         NOT       64       98.5%       100%         Epigastric pain       YES       1       1.5%         NOT       64       98.5%       100%         Chest wall pain       YES       1       1.5%         NOT       64       98.5%       100%         Chest pain       YES       1       1.5%         NOT       64       98.5%       100%         Chest pain       YES       1       1.5%         NOT       64       98.5%       100%         Abdominal pain       YES       1       1.5%         NOT       64       98.5%       100%         Pain crisis       YES       1       1.5%         NOT       64       98.5%       1.5%         NOT       64       98.5%       1.5%         NOT       64       98.5%       1.5%         NOT       64       98.5%       1.5%	, 0	YES	two	3%
Itching  YES two 3% NOT 63 97% TOTAL 65 100%  Dysuria  YES 1 1.5% NOT 64 98.5% TOTAL 65 100%  Epigastric pain  YES 1 1.5% NOT 64 98.5% TOTAL 65 100%  Chest wall pain  YES 1 1.5% NOT 64 98.5% TOTAL 65 100%  Chest wall pain  YES 1 1.5% NOT 64 98.5% TOTAL 65 100%  Chest pain  YES 1 1.5% NOT 64 98.5% TOTAL 65 100%  Chest pain  YES 1 1.5% NOT 64 98.5% TOTAL 65 100%  Abdominal pain  YES 1 1.5% NOT 64 98.5% TOTAL 65 100%  Pain crisis  YES 1 1.5% NOT 64 98.5% TOTAL 65 100%  Pain crisis  YES 1 1.5% NOT 64 98.5% TOTAL 65 100%  Pain crisis  YES 1 1.5% NOT 64 98.5% TOTAL 65 100%  Pain crisis  YES 1 1.5% NOT 64 98.5% TOTAL 65 100%  Dyspnea  YES 1 1.5% NOT 64 98.5% TOTAL 65 100%  Dyspnea		NOT	63	97%
YES two 3% NOT 63 97% TOTAL 65 100%  Dysuria  YES 1 1.5% NOT 64 98.5% TOTAL 65 100%  Epigastric pain  YES 1 1.5% NOT 64 98.5% TOTAL 65 100%  Epigastric pain  YES 1 1.5% NOT 64 98.5% TOTAL 65 100%  Chest wall pain  YES 1 1.5% NOT 64 98.5% TOTAL 65 100%  Chest pain  YES 1 1.5% NOT 64 98.5% TOTAL 65 100%  Chest pain  YES 1 1.5% NOT 64 98.5% TOTAL 65 100%  Abdominal pain  YES 1 1.5% NOT 64 98.5% TOTAL 65 100%  Pain crisis  YES 1 1.5% NOT 64 98.5% TOTAL 65 100%  Pain crisis  YES 1 1.5% NOT 64 98.5% TOTAL 65 100%  Dyspnea  YES 1 1.5% NOT 64 98.5% TOTAL 65 100%  Dyspnea		TOTAL	65	100%
NOT 63 97% TOTAL 65 100%  Dysuria  YES 1 1.5% NOT 64 98.5% TOTAL 65 100%  Epigastric pain  YES 1 1.5% NOT 64 98.5% TOTAL 65 100%  Chest wall pain  YES 1 1.5% NOT 64 98.5% TOTAL 65 100%  Chest wall pain  YES 1 1.5% NOT 64 98.5% TOTAL 65 100%  Chest pain  YES 1 1.5% NOT 64 98.5% TOTAL 65 100%  Abdominal pain  YES 1 1.5% NOT 64 98.5% TOTAL 65 100%  Abdominal pain  YES 1 1.5% NOT 64 98.5% TOTAL 65 100%  Pain crisis  YES 1 1.5% NOT 64 98.5% TOTAL 65 100%  Pain crisis  YES 1 1.5% NOT 64 98.5% TOTAL 65 100%  Dyspnea  YES 1 1.5% NOT 64 98.5% TOTAL 65 100%	Itching			
TOTAL       65       100%         Dysuria         YES       1       1.5%         NOT       64       98.5%         TOTAL       65       100%         Epigastric pain         YES       1       1.5%         NOT       64       98.5%         TOTAL       65       100%         Chest wall pain         YES       1       1.5%         NOT       64       98.5%         TOTAL       65       100%         Abdominal pain         YES       1       1.5%         NOT       64       98.5%         TOTAL       65       100%         Pain crisis         YES       1       1.5%         NOT       64       98.5%         TOTAL       65       100%         Dyspnea         YES       1       1.5%         NOT       64       98.5%         TOTAL       65       100%            Pain crisis		YES	two	3%
Dysuria         YES       1       1.5%         NOT       64       98.5%         TOTAL       65       100%         Epigastric pain         YES       1       1.5%         NOT       64       98.5%         TOTAL       65       100%         Chest wall pain         YES       1       1.5%         NOT       64       98.5%         TOTAL       65       100%         Abdominal pain         YES       1       1.5%         NOT       64       98.5%         TOTAL       65       100%         Pain crisis         YES       1       1.5%         NOT       64       98.5%         TOTAL       65       100%         Dyspnea         YES       1       1.5%         NOT       64       98.5%         TOTAL       65       100%		NOT	63	97%
YES 1 1.5% NOT 64 98.5% TOTAL 65 100%  Epigastric pain  YES 1 1.5% NOT 64 98.5% TOTAL 65 100%  Chest wall pain  YES 1 1.5% NOT 64 98.5% TOTAL 65 100%  Chest pain  YES 1 1.5% NOT 64 98.5% TOTAL 65 100%  Chest pain  YES 1 1.5% NOT 64 98.5% TOTAL 65 100%  Abdominal pain  YES 1 1.5% NOT 64 98.5% TOTAL 65 100%  Abdominal pain  YES 1 1.5% NOT 64 98.5% TOTAL 65 100%  Pain crisis  YES 1 1.5% NOT 64 98.5% TOTAL 65 100%  Dyspnea  YES 1 1.5% NOT 64 98.5% TOTAL 65 100%  Dyspnea		TOTAL	65	100%
NOT 64 98.5% TOTAL 65 100%  Epigastric pain  YES 1 1.5% NOT 64 98.5% TOTAL 65 100%  Chest wall pain  YES 1 1.5% NOT 64 98.5% TOTAL 65 100%  Chest pain  YES 1 1.5% NOT 64 98.5% TOTAL 65 100%  Chest pain  YES 1 1.5% NOT 64 98.5% TOTAL 65 100%  Abdominal pain  YES 1 1.5% NOT 64 98.5% TOTAL 65 100%  Pain crisis  YES 1 1.5% NOT 64 98.5% TOTAL 65 100%  Pain crisis  YES 1 1.5% NOT 64 98.5% TOTAL 65 100%  Dyspnea  YES 1 1.5% NOT 64 98.5% TOTAL 65 100%  Dyspnea	Dysuria			
TOTAL 65 100%  Epigastric pain  YES 1 1.5%  NOT 64 98.5%  TOTAL 65 100%  Chest wall pain  YES 1 1.5%  NOT 64 98.5%  TOTAL 65 100%  Chest pain  YES 1 1.5%  NOT 64 98.5%  TOTAL 65 100%  Chest pain  YES 1 1.5%  NOT 64 98.5%  TOTAL 65 100%  Abdominal pain  YES 1 1.5%  NOT 64 98.5%  TOTAL 65 100%  Pain crisis  YES 1 1.5%  NOT 64 98.5%  TOTAL 65 100%  Pain crisis  YES 1 1.5%  NOT 64 98.5%  TOTAL 65 100%  Dyspnea  YES 1 1.5%  NOT 64 98.5%  TOTAL 65 100%  Dyspnea		YES	1	1.5%
Epigastric pain  YES 1 1.5%  NOT 64 98.5%  TOTAL 65 100%  Chest wall pain  YES 1 1.5%  NOT 64 98.5%  TOTAL 65 100%  Chest pain  YES 1 1.5%  NOT 64 98.5%  TOTAL 65 100%  Chest pain  YES 1 1.5%  NOT 64 98.5%  TOTAL 65 100%  Abdominal pain  YES 1 1.5%  NOT 64 98.5%  TOTAL 65 100%  Pain crisis  YES 1 1.5%  NOT 64 98.5%  TOTAL 65 100%  Pain crisis  YES 1 1.5%  NOT 64 98.5%  TOTAL 65 100%  Dyspnea  YES 1 1.5%  NOT 64 98.5%  TOTAL 65 100%  Dyspnea		NOT	64	98.5%
YES 1 1.5% NOT 64 98.5% TOTAL 65 100%  Chest wall pain  YES 1 1.5% NOT 64 98.5% TOTAL 65 100%  Chest pain  YES 1 1.5% NOT 64 98.5% TOTAL 65 100%  Abdominal pain  YES 1 1.5% NOT 64 98.5% TOTAL 65 100%  Pain crisis  YES 1 1.5% NOT 64 98.5% TOTAL 65 100%  Pain crisis  YES 1 1.5% NOT 64 98.5% TOTAL 65 100%  Dyspnea  YES 1 1.5% NOT 64 98.5% TOTAL 65 100%  Dyspnea		TOTAL	65	100%
NOT 64 98.5% TOTAL 65 100%  Chest wall pain  YES 1 1.5% NOT 64 98.5% TOTAL 65 100%  Chest pain  YES 1 1.5% NOT 64 98.5% TOTAL 65 100%  NOT 64 98.5% TOTAL 65 100%  Abdominal pain  YES 1 1.5% NOT 64 98.5% TOTAL 65 100%  Pain crisis  YES 1 1.5% NOT 64 98.5% TOTAL 65 100%  Point crisis  YES 1 1.5% NOT 64 98.5% TOTAL 65 100%  Dyspnea  YES 1 1.5% NOT 64 98.5% TOTAL 65 100%  Dyspnea	Epigastric pain			
TOTAL 65 100%  Chest wall pain  YES 1 1.5%  NOT 64 98.5%  TOTAL 65 100%  Chest pain  YES 1 1.5%  NOT 64 98.5%  TOTAL 65 100%  Abdominal pain  YES 1 1.5%  NOT 64 98.5%  TOTAL 65 100%  Abdominal pain  YES 1 1.5%  NOT 64 98.5%  TOTAL 65 100%  Pain crisis  YES 1 1.5%  NOT 64 98.5%  TOTAL 65 100%  Dyspnea  YES 1 1.5%  NOT 64 98.5%  TOTAL 65 100%  Dyspnea		YES	1	1.5%
Chest wall pain  YES  NOT  64  98.5%  TOTAL  65  100%  Chest pain  YES  1  1.5%  NOT  64  98.5%  TOTAL  65  100%  Abdominal pain  YES  1  1.5%  NOT  64  98.5%  NOT  64  98.5%  TOTAL  65  100%  Pain crisis  YES  1  1.5%  NOT  64  98.5%  TOTAL  Dyspnea  YES  1  1.5%  NOT  64  98.5%  TOTAL  65  100%		NOT	64	98.5%
YES 1 1.5%  NOT 64 98.5%  TOTAL 65 100%  Chest pain  YES 1 1.5%  NOT 64 98.5%  TOTAL 65 100%  Abdominal pain  YES 1 1.5%  NOT 64 98.5%  TOTAL 65 100%  Pain crisis  YES 1 1.5%  NOT 64 98.5%  TOTAL 65 100%  Poin crisis  YES 1 1.5%  NOT 64 98.5%  TOTAL 65 100%  Dyspnea  YES 1 1.5%  NOT 64 98.5%  TOTAL 65 100%		TOTAL	65	100%
NOT 64 98.5% TOTAL 65 100%  Chest pain  YES 1 1.5% NOT 64 98.5% TOTAL 65 100%  Abdominal pain  YES 1 1.5% NOT 64 98.5% TOTAL 65 100%  Pain crisis  YES 1 1.5% NOT 64 98.5% TOTAL 65 100%  Dyspnea  YES 1 1.5% NOT 64 98.5% TOTAL 65 100%  Dyspnea	Chest wall pain			
TOTAL 65 100%  Chest pain  YES 1 1.5%  NOT 64 98.5%  TOTAL 65 100%  Abdominal pain  YES 1 1.5%  NOT 64 98.5%  TOTAL 65 100%  Pain crisis  YES 1 1.5%  NOT 64 98.5%  TOTAL 65 100%  Dyspnea  YES 1 1.5%  NOT 64 98.5%  TOTAL 65 100%  Dyspnea  YES 1 1.5%  NOT 64 98.5%  TOTAL 65 100%		YES	1	1.5%
Chest pain  YES  1  1.5%  NOT  64  98.5%  TOTAL  65  100%  Abdominal pain  YES  1  1.5%  NOT  64  98.5%  TOTAL  65  100%  Pain crisis  YES  1  1.5%  NOT  64  98.5%  TOTAL  55  100%  Dyspnea  YES  1  1.5%  NOT  64  98.5%  TOTAL  65  100%		NOT	64	98.5%
YES 1 1.5%  NOT 64 98.5%  TOTAL 65 100%  Abdominal pain  YES 1 1.5%  NOT 64 98.5%  TOTAL 65 100%  Pain crisis  YES 1 1.5%  NOT 64 98.5%  TOTAL 65 100%  Dyspnea  YES 1 1.5%  NOT 64 98.5%  TOTAL 65 100%		TOTAL	65	100%
NOT 64 98.5% TOTAL 65 100%  Abdominal pain  YES 1 1.5% NOT 64 98.5% TOTAL 65 100%  Pain crisis  YES 1 1.5% NOT 64 98.5% NOT 64 98.5% TOTAL 65 100%  Dyspnea  YES 1 1.5% NOT 64 98.5% NOT 64 98.5% NOT 64 98.5%	Chest pain			
TOTAL 65 100%  Abdominal pain  YES 1 1.5%  NOT 64 98.5%  TOTAL 65 100%  Pain crisis  YES 1 1.5%  NOT 64 98.5%  TOTAL 65 100%  Dyspnea  YES 1 1.5%  NOT 64 98.5%  TOTAL 65 100%		YES	1	1.5%
Abdominal pain  YES 1 1.5%  NOT 64 98.5%  TOTAL 65 100%  Pain crisis  YES 1 1.5%  NOT 64 98.5%  TOTAL 65 100%  Dyspnea  YES 1 1.5%  NOT 64 98.5%  TOTAL 65 100%		NOT	64	98.5%
YES 1 1.5%  NOT 64 98.5%  TOTAL 65 100%  Pain crisis  YES 1 1.5%  NOT 64 98.5%  TOTAL 65 100%  Dyspnea  YES 1 1.5%  NOT 64 98.5%  TOTAL 65 100%		TOTAL	65	100%
NOT 64 98.5% TOTAL 65 100%  Pain crisis  YES 1 1.5% NOT 64 98.5% TOTAL 65 100%  Dyspnea  YES 1 1.5% NOT 64 98.5% NOT 64 98.5%	Abdominal pain			
TOTAL 65 100%  Pain crisis  YES 1 1.5%  NOT 64 98.5%  TOTAL 65 100%  Dyspnea  YES 1 1.5%  NOT 64 98.5%  NOT 64 98.5%		YES	1	1.5%
Pain crisis  YES 1 1.5%  NOT 64 98.5%  TOTAL 65 100%  Dyspnea  YES 1 1.5%  NOT 64 98.5%		NOT	64	98.5%
YES 1 1.5% NOT 64 98.5% TOTAL 65 100%  Dyspnea  YES 1 1.5% NOT 64 98.5%		TOTAL	65	100%
NOT 64 98.5% TOTAL 65 100% Dyspnea YES 1 1.5% NOT 64 98.5%	Pain crisis			
TOTAL         65         100%           Dyspnea         YES         1         1.5%           NOT         64         98.5%		YES	1	1.5%
Dyspnea           YES         1         1.5%           NOT         64         98.5%		NOT	64	98.5%
YES 1 1.5% NOT 64 98.5%		TOTAL	65	100%
NOT 64 98.5%	Dyspnea			
		YES	1	1.5%
TOTAL 65 100%		NOT	64	98.5%
		TOTAL	65	100%

Rev Med Minas Gerais 2023; 33: e-33102

Table 5. Laboratory tests of the pediatric patients studied.

Median	Minimum	Maximum
11,315	2,600	205,100
	TOTAL: 64	
2,983	506	123,060
	TOTAL: 64	
332,000	20,000	1,027,000
	TOTAL: 64	
12	0.5	291
	TOTAL: 63	
285	74	1,766
	TOTAL: 57	
1,243	187	103,851
	TOTAL: 20	
20.3	2.7	39
	TOTAL: 60	
0.2	0.2	0.8
	TOTAL: 60	
92	20	40,000
<i>7</i> -	TOTAL: 52	,
95.3		924
)).3		)24
	11,315 2,983 332,000	11,315 2,600 TOTAL: 64  2,983 506 TOTAL: 64  332,000 20,000 TOTAL: 64  12 0.5 TOTAL: 63  285 74 TOTAL: 57  1,243 187 TOTAL: 20  20.3 2.7 TOTAL: 60  0.2 0.2 TOTAL: 60  92 20 TOTAL: 52

The difference between the total of 65 cases studied and the total number of cases in the column of each variable refers to the number of cases in which such exams were not collected.

The length of stay varied: 15 (23.1%) patients stayed for less than 3 days in the hospital unit, 32 (49.2%) stayed between 3 and 7 days, and 18 (27.7%) needed more 7 days of hospitalization. Only 3 patients (4.5%) were transferred from the ward to the ICU, with 2 of them later returning to the sector. Regarding the outcome, 64 (98.5%) were discharged from the HRJP. Only 1 patient, whose comorbidities were congenital toxoplasmosis, congenital laryngomalacia with severe respiratory discomfort, hypoaldosteronism/pseudohypoaldosteronism and neuropsychomotor development delay, had an unfavorable outcome, evolving to death.

# **DISCUSSION**

It was observed that children under 3 years of age represented most hospitalized individuals (49.2%), which is consistent with what is found in the literature, in which children under 2 years of age are risk group<sup>11,12</sup>. There was also a predominance of males, representing 66.2% of cases. According to Mjaess et al. (2020)<sup>13</sup>, male predominance

is still not well understood, but there are indications that estrogen may have a protective effect against coronavirus infection. In addition, viral pathogenicity itself may be responsible for this difference, as the infectivity of the coronavirus depends on the binding of its viral spike protein to the angiotensin-converting enzyme 2 (ACE2) receptor, and that there is an increase in ACE2 expression in male individuals<sup>13</sup>. Regarding to ethnicity, there was no significant difference between groups; and as for territorial distribution, there was a homogeneous distribution among the city's neighborhoods, with no predominance of any region.

Most hospitalized patients were referred from emergency care units and presented less than 5 days of symptoms at the time of hospitalization, which is contrary to literature data, which patients evolve with worsening of symptoms after the 7<sup>th</sup> day of illness<sup>14</sup>.

Three cases of symptomatic newborns were found with samples collected with less than 24 hours of life and positive results, which indicates vertical transmission, but a separate study is needed, with a representative sample to better establish the characteristics of the disease in this group.



Among comorbidities, the most frequent was chronic respiratory disease, representing 26.2% of the sample. This finding agrees with studies that state that this comorbidity represents a risk factor for complications in COVID-19<sup>15</sup>. Another group that deserves mention is that of oncohematological diseases, in the sample this was the second most prevalent group, and this fact can be attributed to the impairment of the immune system of patients undergoing cancer treatment<sup>16</sup>.

Clinical and epidemiological features of pediatric patients with COVID-19

The most prevalent clinical condition was respiratory, representing more than 70% of cases, followed by gastrointestinal symptoms, about 12% of cases, which appeared as an isolated case, but mainly associated with respiratory symptoms, which is already common in other cases of viral infections<sup>17</sup>. Several other signs and symptoms were observed in the sample group, drawing attention to the variability of the clinical presentation of COVID-19 in pediatrics. Studies show that this variation may be related to the patients' previous health status, at the time the child was taken to the care and the presence of comorbidities<sup>18</sup>. Regarding the lower severity and good evolution of the cases observed in the child population in general, it is believed to be related to the later exposure of children to the virus, due to social isolation and home confinement, causing them to be exposed to less virulent strains. Added to this, the theory of the trained immunity - caused using certain vaccines to train innate immunity to acquire immunological memory; and the lower number of ACE2 receptors found in children - which likely allow SARS-CoV-2 to enter host cells. In addition, children tend to have fewer comorbidities than adults and may have a greater number of other viruses in their respiratory mucosa, which would limit the growth of SARS-CoV-219.

In the sample, there were no cases of pediatric inflammatory multisystem syndrome (SIM-P), a severe form of hyperinflammatory reactions that resembles Kawasaki disease (KD) - self-limited acute febrile vasculitis of unknown etiology, responsible for the major cause of acquired heart disease in developed countries. In KD, vascular inflammation occurs that predominantly affects medium-sized vessels, with a predilection for coronary arteries, which can lead to aneurysms, thrombosis and stenosis, evolving to infarction or sudden death. But, despite not being frequent, such cases have already been reported by other services 19,20.

In the present study, no alterations were found related to laboratory tests that could generate a high degree of suspicion for COVID-19. When observing the median, global leukocytes, CRP and LDH presented values slightly above the reference value; lymphocytes, platelets, urea, creatinine, CPK and ferritin were normal; D-dimer was the only marker that was found well above the reference value, justified by the fact that it is a product of fibrin degradation, and this process is increased in conditions such as sepsis, vasculitis, trauma and other situations of stress and inflammatory diseases<sup>21</sup>.

Regarding imaging tests, characteristic changes were not found on radiographs, but on CT scans of the chest, ground-glass opacity was observed in about 65% of cases, which suggests viral infection, but is not specific to COVID-19<sup>22</sup>.

Regarding pharmacological therapy, in more than 50% of the sample, azithromycin was used. Ceftriaxone or amoxicillin + clavulanate were used in some cases due to associated secondary bacterial infection, with the form of presentation varying according to the general status and acceptance of the child. However, it is important to emphasize that the irrational use of antibiotics, especially those with a broad spectrum, should be avoided, always paying attention to the real need for prescription, as in cases of clinical deterioration of patients and/or presence of positive cultures<sup>23</sup>. Azithromycin, a broad-spectrum macrolide antibiotic with anti-inflammatory properties, can act in several types of infection, including respiratory. However, there is no evidence of these benefits in COVID-19, thus not justifying its prescription in treatment<sup>24</sup>.

Intravenous corticosteroids were prescribed to approximately 35.4% of patients, switching as soon as possible to oral prednisolone, which in total was used in 47.7% of these patients. However, the use of these medications should also be judicious, based on the severity of the systemic inflammatory response, the degree of dyspnea, rapid radiological deterioration or other serious complications such as septic shock<sup>23</sup>. In patients who required oxygen therapy, especially mechanical ventilation, early administration of dexamethasone was able to reduce the duration of oxygen delivery and even mortality<sup>24</sup>.

#### CONCLUSION

In the present study, it was observed that age below 3 years and presence of chronic respiratory disease were risk factors for hospitalization in Covid-19 cases. Most of the hospitalizations occurred until the 5<sup>th</sup> day of symptoms, lasted on average up to 7 days and had a good evolution with a favorable outcome. There was only one death in a patient with multiple comorbidities.

COVID-19 has varied clinical, radiological and laboratory presentations and, since there is no single or specific treatment, cases must be analyzed and managed individually.

# **AUTHORS CONTRIBUTION**

Dayra Aparecida de Almeida Pinheiro: Conceptualization, data curation, formal analysis and writing (original draft, review and editing). Eliza Lavall Bamberg: Data curation, formal analysis and writing (original draft). Ana Clara Ribeiro de Barros Pereira: Data curation, formal analysis and writing (original draft). Fábio Videira Chagas: Data curation and formal analysis. Sílvia Paschoalini Azalim de Castro: Conceptualization, formal analysis, writing (review and editing) and supervision.



# **COPYRIGHT**

Copyright<sup>®</sup> 2021 Pinheiro et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 International License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original article is properly cited.

# REFERENCES

- Shen KL, Yang YH, Jiang RM, Wang TY, Zhao DC, Jiang Y, et al. Updated diagnosis, treatment and prevention of COVID-19 in children: experts' consensus statement (condensed version of the second edition). World J Pediatr. 2020 Jun;16(3):232-9.
- Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020 Feb;395(10224):565-74.
- Yu Y, Chen P. Coronavirus disease 2019 (COVID-19) in neonates and children from china: a review. Front Pediatr. 2020 May;8:287.
- Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb;395(10223):497-506.
- Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020 Mar;323(11):1061-9.
- Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020 Apr;382(18):1708-20.
- Fang F, Chen Y, Zhao D, Liu T, Huang Y, Qiu L, et al. Recommendations for the diagnosis, prevention, and control of coronavirus disease-19 in children-the Chinese perspectives. Front Pediatr. 2020 Nov;8:553394.
- 8. Dong Y, Mo X, Hu Y, Qi X, Jiang F, Jiang Z, et al. Epidemiology of COVID-19 among children in China. Pediatrics. 2020 Jun;145(6):e20200702.
- Safadi MAP. The intriguing features of COVID-19 in children and its impact on the pandemic. J Pediatr (Rio J). 2020 May/ Jun;96(3):265-8.
- Ministério da Saúde (BR). Protocolo de manejo clínico da Covid-19 na Atenção Especializada [Internet]. Brasília (DF): Ministério da Saúde; 2021; [access in 2020 Oct 20]. Available from: https://bvsms.saude.gov.br/bvs/publicacoes/manejo\_ clinico\_covid-19\_atencao\_especializada.pdf

- Kim L, Whitaker M, O'Halloran A, Kambhampati A, Chai SJ, Reingold A, et al. Hospitalization rates and characteristics of children aged <18 years hospitalized with laboratory-confirmed COVID-19 - COVID-NET, 14 States, March 1-July 25, 2020. Morb Mortal Wkly Rep. 2020 Aug;69(32):1081-8.
- Sousa BLA, Silva CA, Ferraro AA. A epidemiologia da COVID-19 pediátrica no Brasil: uma atualização. Rev Paul Pediatr. 2022;40:e2021367.
- Mjaess G, Karam A, Aoun F, Albisinni S, Roumeguère T. COVID-19 and the male susceptibility: the role of ACE2, TMPRSS2 and the androgen receptor. Prog Urol. 2020. Sep;30(10):484-7.
- Fernandes F, Ramires FJA, Fernandes FD, Simóes MV, Mesquita ET, Mady C. Pericardial affections in patients with COVID-19: a possible cause of hemodynamic deterioration. Arq Bras Cardiol. 2020 Sep;115(3):569-73.
- Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020 Mar;368:m1091.
- 16. Ferreira JD, Lima FCS, Oliveira JFP, Cancela MC, Santos MO. COVID-19 and cancer: updating epidemiological issues. Rev Bras Cancerol. 2020;66:e-1013.
- Pitrez PMC, Pitrez JLB. Acute upper respiratory tract infections: outpatient diagnosis and treatment. J Pediatr (Rio J). 2003 May;79(Suppl 1):S77-S86.
- Ji LN, Chao S, Wang YJ, Li XJ, Mu XD, Lin MG, et al. Clinical features of pediatric patients with COVID-19: a report of two family cluster cases. World J Pediatr. 2020 Jun;16(3):267-70. DOI: https://doi.org/10.1007/s12519-020-00356-2
- Abdel-Aziz M, Abdel-Aziz NM, Abdel-Aziz DM, Azab N. Pediatric COVID-19 and the factors that may mitigate its clinical course. J Child Sci. 2020;10(1):137-40.
- Gandra GA, Alves SSC, Gandra KN, Costa ALDG, Medeiros RF, Freitas RAS, et al. Kawasaki disease: the importance of its diagnosis in different age groups. Rev Med Minas Gerais. 2018;28:e1942.
- 21. Terra-Filho M, Menna-Barreto SS. Recommendations for the management of pulmonary thromboembolism, 2010. J Bras Pneumol. 2010 Mar;36(Suppl 1):S1-S68.
- Matos MJR, Rosa MEE, Brito VM, Amaral LTW, Beraldo GL, Fonseca EKUN, et al. Differential diagnoses of acute ground-glass opacity in chest computed tomography: pictorial essay. Einstein. 2021 Mar;19:eRW5772.
- 23. Silva FS, Ferraz RRN. Treatments for COVID-19: synthesis of evidence. Int J Health Manag Rev. 2020;6(1):1-9.
- 24. Ferreira ACP, Lopes SMG, Morais SR, Carneiro CC. Tratamento da Covid-19 -protocolos atuais e perspectivas futuras. RECIMA21. 2021 May;2(4):e24251.

